129
Views
3
CrossRef citations to date
0
Altmetric
Review

Umbilical cord blood: biology and transplantation

&
Pages 197-208 | Published online: 10 Jan 2014

References

  • Mayani H, Lansdorp PM. Biology of human umbilical cord blood-derived hematopoietic stem/progenitor cells. Stem Cells16(3), 153–165 (1998).
  • Traycoff CM, Abboud MR, Laver J et al. Evaluation of the in vitro behavior of phenotypically defined populations of umbilical cord blood hematopoietic progenitor cells. Exp. Hematol.22(2), 215–222 (1994).
  • Broxmeyer HE, Hangoc G, Cooper S et al. Growth characteristics and expansion of human umbilical cord blood and estimation of its potential for transplantation in adults. Proc. Natl Acad. Sci. USA89(9), 4109–4113 (1992).
  • Hows JM, Bradley BA, Marsh JCW et al. Growth of human umbilical cord blood in long-term hematopoietic cultures. Lancet340(8811), 73–76 (1992).
  • Mayani H, Gutierrez-Rodriguez M, Espinoza l et al. Kinetics of hematopoiesis in Dexter-type long-term cultures established from human umbilical cord blood cells. Stem Cells16(2), 127–135 (1998).
  • McNiece IK, Stewart FM, Deacon DM et al. Detection of a human CFC with a high proliferative potential. Blood74(2), 609–615 (1989).
  • Lu L, Xiao M, Shen R-N, Grisby S, Broxmeyer HE. Enrichment, characterization and responsiveness of single primitive CD34 human umbilical cord blood hematopoietic progenitors with high proliferative and replating potential. Blood81(1), 41–48 (1993).
  • Vaziri H, Dragowska W, Allsopp RC, Thomas TE, Harley CB, Lansdrop PM. Evidence for a mitotic clock in human hematopoietic stem cells: loss of telomeric DNA with age. Proc. Natl Acad. Sci. USA91(21), 9857–9860 (1994).
  • Pentengell R, Luft T, Henschler R et al. Direct comparison by limiting dilution analysis of long-term culture initiating cells in human bone marrow, umbilical cord blood and blood stem cells. Blood84(11), 3652–3659 (1994).
  • Han P, Hodge G, Story C, Xu X. Phenotypic analysis of functional T-lymphocytes and natural killer cells in human cord blood: relevance to umbilical cord blood transplantation. Br. J. Haematol.89(4), 733–740 (1995).
  • Szabolcs P, Park KD, Reese M, Marti L, Broadwater G, Kurtzberg J. Coexistent naïve phenotype and higher cycling rate of cord blood T cells as compared to adult peripheral blood. Exp. Hematol.31(8), 708–714 (2003).
  • Chalmers IM, Jannossy, Contreras M, Navarrete C. Intracellular cytokine profile of cord and adult blood lymphocytes. Blood92(1), 11–18 (1998).
  • Kollet O, Spiegel A, Peled A et al. Rapid and efficient homing of human CD34(+)CD38(/low)CXCR4(+) stem and progenitor cells to the bone marrow and spleen of NOD/SCID and NOD/SCID/B2m(null) mice. Blood97(10), 3283–3291 (2001).
  • Peled A, Kollet O, Ponomarylov T et al. The chemokine SDF-1 activates the integrins LFA-1, VLA-4, and VLA-5 on immature human CD34+ cells: role in the transendothelial/stromal migration and engraftment in NOD/SCID mice. Blood95(11), 3289–3296 (2000).
  • Lapidot T, Dar A, Kollet O. How do stem cells find their way home? Blood106(6), 1901–1910 (2005).
  • Peled A, Petit I, Kollet O et al. Dependence of human stem cell engraftment and repopulation of NOD/SCID mice in CXCR4. Science283(5403), 845–848 (1999).
  • Petit I, Szyper-Kravitz M, Nagler A et al. G-CSF induces stem cell mobilization by decreasing bone marrow sdf-1 and up-regulating CXCR4. Nat. Immunol.3(7), 687–694 (2002).
  • Kahn J, Byk T, Jansson-Sjostrand L et al. Overexpression of CXCR4 on human CD34+ progenitors increases their proliferation, migration, and NOD/SCID repopulation. Blood103(8), 2942–2949 (2004).
  • Glimm H, Tang P, Clark-Lewis I et al.Ex vivo treatment of proliferating human cord blood stem cells with stroma-derived factor-1 enhances their ability to engraft NOD/SCID mice. Blood99(9), 3454–3457 (2002).
  • Roy V, Verfaillie CM. Expression and function of cell adhesion molecules on fetal liver, cord blood and bone marrow hematopoietic progenitors: implications for anatomic localization and developmental stage specific regulation of hematopoiesis. Exp. Hematol.27(2), 302–312 (1999).
  • Ng YY, van Kessel B, Lokhorst HM et al. Gene-expression profiling of CD34+ cells from various hematopoietic stem-cell sources reveals functional differences in stem-cell activity. J. Leukoc. Biol.75(2), 314–323 (2004).
  • Parkman R, Cohen G, Carter SL et al. Successful immune reconstitution decreases leukemic relapse and improves survival in recipients of unrelated cord blood transplantation. Biol. Blood Marrow Transplant.12(9), 919–927 (2006).
  • Kamanduri KV, St John LS, de Lima M et al. Delayed immune reconstitution after cord blood transplantation is characterized by impaired thymopoiesis and late memory T-cell skewing. Blood110(13), 4543–4551 (2007).
  • Parody R, Martino R, Rovina M et al. Severe infections after unrelated donor allogeneic hematopoietic stem cell transplantation in adults: comparison of cord blood transplantation with peripheral blood and bone marrow transplantation. Biol. Blood Marrow Transplant.12(7), 734–748 (2006).
  • Brunstein CG, Weisdorf DJ, Defor T et al. Marked increased risk of Epstein–Barr virus-related complications with the addition of antithymocyte globulin to a nonmyeloablative conditioning prior to unrelated umbilical cord blood transplantation. Blood108(8), 2874–2880 (2006).
  • Albano MS, Taylor P, Pass RF et al. Umbilical cord blood transplantation and cytomegalovirus: post-transplantation infection and donor screening. Blood108(13), 4275–4282 (2006).
  • Civin CI, Strauss LC, Brovall C, Fackler MJ, Schwartz JF, Shaper JH. Antigenic analysis of hematopoiesis III. A hematopoietic progenitor cell surface antigen defined by a monoclonal antibody raised against KG-Ia cells. J. Immunol.133(1), 157–165 (1984).
  • Healy L, May G, Gale K, Grosveld F, Greaves M, Enver T. The stem cell antigen CD34 functions as a regulator of hematopoietic cell adhesion. Proc. Natl Acad. Sci. USA92(26) 12240–12244 (1995).
  • Kinniburgh D, Russell NH. Comparative study of CD34-positive cells and subpopulations in human umbilical cord blood and bone marrow. Bone Marrow Transplant.12(5), 489–494 (1993).
  • Thilaganathan B, Nicolaides KH, Morgan G. Subpopulations of CD34-positive haematopoietic progenitors in fetal blood. Br. J. Haematol.87(3), 634–636 (1994).
  • Craig W, Kay R, Cutler RL, Lansdrop PM. Expression of Thy-1 on human hematopoietic progenitor cells. J. Exp. Med.177(5), 1331–1338 (1993).
  • Mayani H, Lansdrop PM. Thy-1 expression is linked to functional properties of primitive hematopoietic progenitor cells from human umbilical cord blood. Blood83(9), 2410–2417 (1994).
  • Anderson DM, Lyman SD, Baird A et al. Molecular cloning of mast cell growth factor, a hemopoietin that is active in both membrane bound and soluble forms. Cell63(1), 235–242 (1990).
  • Rappold I, Ziegler BL, Köhler I et al. Functional and phenotypic characterization of cord blood and bone marrow subsets expressing FLT3 (CD135) receptor kinase. Blood90(1), 111–125 (1997).
  • Saeland S, Duvert V, Caux C et al. Distribution of surface-membrane molecules on bone marrow and cord blood CD34+ hematopoietic cells. Exp. Hematol.20(1), 24–33 (1992).
  • Kimura T, Asada R, Wang J et al. Identification of long-term repopulating potential of human cord blood-derived CD34-flt3-severe combined immunodeficiency-repopulating cells by intrabone marrow injection. Stem Cells25(6), 1348–1355 (2007).
  • López MC, Palmer BE, Lawrence DA. Phenotypic differences between cord blood and adult peripheral blood. Cytometry B Clin. Cytom.76B(1), 37–46 (2008).
  • Wagner JE, Barker JN, Defor TE et al. Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival. Blood100(5), 1611–1618 (2002).
  • Godfrey WR, Spoden DJ, GeYG et al. Cord blood CD4+CD25+-derived T regulatory cells lines express FoxP3 protein and manifest potent suppressor function. Blood105(2), 750–758 (2005).
  • Li L, Godfrey WR, Porter SB et al. CD4+CD25+ regulatory T cell lines from human cord blood have functional and molecular properties of T cell anergy. Blood106(9), 3068–3073 (2005).
  • Zhao Y, Lin B, Darflinger R, Zhang Y, Holterman MJ, Skidgel RA. Human cord blood stem cell- modulated regulatory T lymphocytes reverse the autoimmune caused-type I diabetes in nonobese diabetic (NOD) mice. PLoS ONE4(1), e4226 (2009).
  • Van Rood JJ, Oudshoorn M. Eleven million donors in bone marrow donors worldwide! Time for reassessment? Bone Marrow Transplant.41(1), 1–9 (2008).
  • McCullough J, McKenna D, Kadidlo D, Schierman T, Wagner J. Issues in the quality of umbilical cord blood stem cells for transplantation. Transfusion45(6), 832–841 (2005).
  • Ballen KK, Barker JN, Stewart SK, Greene MF, Lane TA. Collection and preservation of cord blood for personal use. Biol. Blood Marrow Transplant.14(3), 356–363 (2008).
  • American Academy of Pediatrics WGOCBB. Cord blood banking for potential future transplantation: subject review. American Academy of Pediatrics. Work Group on Cord Blood Banking. Pediatrics104(1 Pt 1), 116–118 (1999).
  • Committee on Obstetric Practice; committee on genetics. ACOG committee opinion number 399, February 2008: umbilical cord blood banking. Obstet. Gynecol.111(2 Pt 1), 475–477 (2008).
  • Gluckman E, Rocha V, Arcese W et al. Factors associated with outcomes of unrelated cord blood transplant: guidelines for donor choice. Exp. Hematol.32(4), 397–407 (2004).
  • Rubinstein P, Stevens CE. Placental blood for bone marrow replacement: the New York Blood Center’s program and clinical results. Baillieres Best Pract. Res. Clin. Haematol.13(4), 565–584 (2000).
  • Gluckman E, Rocha V, Boyer-Chammard A et al. Outcome of cord-blood transplantation from related and unrelated donors: Eurocord Transplant Group and the European Blood and Marrow Transplantation Group. N. Engl. J. Med.337(6), 373–381 (1997).
  • Barker J, Scaradavou A, Stevens C, Rubinstein P. Analysis of 608 umbilical cord blood transplants: HLA-match is a critical determinant of transplant-related mortality in the post-engraftment period evening the absence of acute graft-versus-host disease. Blood106, (2005) (Abstract 303).
  • Gluckman E, Rocha V. Donor selection for unrelated cord blood transplants. Curr. Opin. Immunol.18(5), 565–570 (2006).
  • Gluckman E, Broxmeyer HA, Auerbach AD et al. Hematopoietic reconstitution in a patient with Fanconi’s anemia by means of umbilical-cord blood from an HLA-identical sibling. N. Engl. J. Med.321(17), 1174–1178 (1989).
  • Kurtzberg J, Laughlin M, Graham ML et al. Placental blood as a source of hematopoietic stem cells for transplantation into unrelated recipients. N. Engl. J. Med.335(3), 157–166 (1996).
  • Eapen M, Rubinstein P, Zhang M-J et al. Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukemia: a comparison study. Lancet369(9577), 1947–1954 (2007).
  • Locatelli F, Nöllke P, Zecca M et al. Hematopoietic stem cell transplantation (HSCT) in children with juvenile myelomonocytic leukemia (JMML): results of the EWOG-MDS/EBMT trial. Blood105(1), 410–419 (2004).
  • Kurtzberg J, Prasad VK, Carter S et al. Results of the Cord Blood Transplantation Study (COBLT): clinical outcomes of unrelated donor umbilical cord blood transplantation in pediatric patients with hematologic malignancies. Blood112(10), 4318–4327 (2008).
  • Escolar ML, Poe MD, Provenzale JM et al. Transplantation of umbilical cord blood in babies with infantile Krabbe’s disease. N. Engl. J. Med.352(20), 2069–2081 (2005).
  • Laughlin MJ, Eapen M, Rubinstein P et al. Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. N. Engl. J. Med.351(22), 2265–2275 (2004).
  • Rocha V, Labopin M, Sanz G et al. Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia. N. Engl. J. Med.351(22), 2276–2285 (2004).
  • Takahashi S, Iseki T, Ooi J et al. Single-institute comparative analysis of unrelated bone marrow transplantation and cord blood transplantation for adult patients with hematologic malignancies. Blood104(12), 3813–3820 (2004).
  • Takahashi S, Ooi J, Tomonari A et al. Comparative single-institute analysis of cord blood transplantation from unrelated donors with bone marrow or peripheral blood stem-cell transplants from related donors in adult patients with hematologic malignancies after myeloablative conditioning regimen. Blood109(3), 1322–1330 (2007).
  • Cornetta K, Laughlin M, Cater S et al. Umbilical cord blood transplantation in adults: results of the prospective cord blood transplantation (COBLT). Biol. Blood Marrow Transplant.11(2), 149–160 (2005).
  • Kumar P, Defor TE, Brunstein C et al. Allogeneic hematopoietic stem cell transplantation in adult acute lymphocytic leukemia: impact of donor source on survival. Biol. Blood Marrow Transplant.14(12), 1394–1400 (2008).
  • Rodrigues CA, Sanz G, Brunstein CG et al. Analysis of risk factors for outcomes after unrelated cord blood transplantation in adults with lymphoid malignancies: a study by the Eurocord-Netcord and Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J. Clin. Oncol.27(2), 256–263 (2009).
  • Barker JN, Weisdorf DJ, Defor TE et al. Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy. Blood105(3), 1343–1347 (2005).
  • Macmillan ML, Weisdorf DJ, Brunstein CG et al. Acute graft-versus-host disease after unrelated donor umbilical cord blood transplantation: analysis of risk factors. Blood113(11), 2410–2415 (2008).
  • Arora M, Nagaraj S, Wagner JE et al. Chronic graft-versus-host disease (cGVHD) following unrelated donor hematopoietic stem cell transplantation (HSCT): higher response rate in recipients of unrelated donor (URD umbilical cord blood (UCB). Biol. Blood Marrow Transplant.13(10), 1145–1152 (2007).
  • Mazurier F, Doedens M, Gan OI, Dick JE. Rapid myeloerythroid repopulation after intrafemoral transplantation of NOD–SCID mice reveals a new class of human stem cells. Nat. Med.9(7), 959–963 (2003).
  • Klimczak A, Unal S, Jankowska A, Coburn C, Siemionow M. Donor-origin cell engraftment after intraosseous or intravenous bone marrow transplantation in a rat model. Bone Marrow Transplant.40(4), 373–380 (2007).
  • Frassoni F, Gualandi F, Podesta M et al. Direct intrabone transplant of unrelated cord-blood cells in acute leukaemia: a Phase I/II study. Lancet Oncol.9(9), 831–839 (2008).
  • Rizzieri DA, Long, GD, Vredenburg JJ et al. Successful allogeneic engraftment of mismatched unrelated cord blood following a nonmyeloablative preparative regimen. Blood98(12), 3486–3488 (2001).
  • Barker JN, Weisdorf DJ, Defor TE, Blazer BR, Miller JS, Wagner JE. Rapid and complete donor chimerism in adult recipients of unrelated donor umbilical cord blood transplantation after reduced-intensity conditioning. Blood102(5), 1915–1919 (2003).
  • Koh L-P, Chao NJ. Umbilical cord blood transplantation in adults using myeloablative and nonmyeloablative preparative regimens. Biol. Blood Marrow Transplant.10(1), 1–22 (2004).
  • Brunstein CG, Barker JN, Weisdorf DJ et al. Umbilical cord blood transplantation after nonmyeloablative conditioning: impact on transplantation outcomes in 110 adults with hematologic disease. Blood110(8), 3064–3070 (2007).
  • Majhail NS, Brunstein CG, Tomblyn M et al. Reduced-intensity allogeneic transplant in patients older than 55 years: unrelated umbilical cord blood is safe and effective for patients without a matched related donor. Biol. Blood Marrow Transplant.14(3), 282–289 (2008).
  • Majhail NS, Weisdorf DJ, Wagner JE, Defor TE, Brunstein CG, Burns LJ. Comparable results of umbilical cord blood and HLA-matched sibling donor hematopoietic stem cell transplantation after reduced-intensity preparative regimen for advanced Hodgkin lymphoma. Blood107(9), 3804–3807 (2006).
  • Mimeault M, Hauke R, Batra SK. Stem cells: a revolution in therapeutics – recent advances in stem cell biology and their therapeutic applications in regenerative medicine and cancer therapies. Clin. Pharmacol. Ther.82(3), 252–264 (2007).
  • Murohara T, Ikeda H, Duan J et al. Transplanted cord blood-derived endothelial precursor cells augment postnatal neovascularization. J. Clin. Invest.105(11), 1527–1536 (2000).
  • Pomyje J, Zivny J, Sefc L, Plasilova M, Pytlik R, Necas E. Expression of genes regulating angiogenesis in human circulating hematopoietic cord blood CD34+/CD133+ cell. Eur. J. Haematol.70(3), 143–150 (2003).
  • Ma N, Stamm C, Kaminski A et al. Human cord blood cells induce angiogenesis following myocardial infarction in NOD/SCID-mice. Cardiovasc. Res.66(1), 45–54 (2005).
  • Hu CH, Wu GF, Wang XQ et al. Transplanted human umbilical cord blood mononuclear cells improve left ventricular function through angiogenesis in myocardial infarction. Chin. Med. J. (Engl.)119(18), 1499–1506 (2006).
  • Kim BO, Tian H, Prasongsukarn K et al. Cell transplantation improves ventricular function after a myocardial infarction: a preclinical study of human unrestricted somatic stem cells in a porcine model. Circulation112(9 Suppl.), I96–I104 (2005).
  • Bachsetter AD, Pabon MM, Col MJ et al. Peripheral injection of human umbilical cord blood stimulates neurogenesis in the aged rat brain. BMC Neurosci.9(1), 22–30 (2008).
  • Lu D, Sanberg PR, Mahmood A et al. Intravenous administration of human umbilical cord blood reduces neurological deficit in the rat after traumatic brain injury. Cell Transplant.11(3), 275–281 (2002).
  • Zhao ZM, Li HJ, Liu HY. Intraspinal transplantation of CD34+ human umbilical cord blood cells after spinal cord hemisection injury improves functional recovery in adult rats. Cell Transplant.13(3), 113–122 (2004).
  • Chen N, Hudson JE, Walczak P et al. Human umbilical cord blood progenitors: the potential of these hematopoietic cells to become neural. Stem Cells23, 156–170 (2005).
  • Zangiacomi V, Balon N, Maddens S et al. Cord blood-derived neurons are originated from CD133+/CD34 stem/progenitor cells in a cell-to-cell contact dependent manner. Stem Cells Dev.17(5), 1005–1016 (2008).
  • Piacibello W, Sanavio F, Garetto L et al. Extensive amplification and self-renewal of human primitive hematopoietic stem cells from cord blood. Blood89(8), 2644–2653 (1997).
  • Lim CK, Sun L, Feng Q. Effect of anti-52 antibody alemtuzumab on ex-vivo culture of umbilical cord blood stem cells. J. Hematol. Oncol.1, 19–29 (2008).
  • De Felice L, Tatarelli C, Mascolo MG et al. Histone deacetylase inhibitor valproic acid enhances the cytokine-induced expansion of human hematopoietic stem cells. Cancer Res.65(4), 1505–1513 (2005).
  • Karanu FN, Murdoch B, Gallacher L et al. The Notch ligand Jagged-1 represents a novel growth factor of human hematopoietic stem cells. J. Exp. Med.192(9), 1365–1372 (2000).
  • Reya T, Duncan AW, Ailles L et al. A role for Wnt signaling in self-renewal of haematopoietic stem cells. Nature423(6938), 409–414 (2003).
  • Bakshi T, Zabriske RC, Bodie S et al. Mesenchymal stem cells from the Wharton’s jelly of umbilical cord segments provide stromal support for the maintenance of cord blood hematopoietic stem cells during long-term ex vivo culture. Transfusion48(12), 2638–2644 (2008).
  • Chan SL, Choi M, Wnendt S et al. Enhanced in vivo homing of uncultured and selectively amplified cord blood CD34+ cells by cotransplantation with cord blood-derived unrestricted somatic stem cells. Stem Cells25(2), 529–536 (2007).
  • Robinson SN, Ng J, Niu T et al. Superior ex vivo cord blood expansion following co-culture with bone marrow-derived mesenchymal stem cells. Bone Marrow Transplant.37(4), 359–366 (2006).
  • Shpall EJ, Quinones R, Giller R et al. Transplantation of ex vivo expanded cord blood. Biol. Blood Marrow Transplant.8(7), 368–376 (2002).
  • Wagner JE, Rosenthal J, Sweetman R et al. Successful transplantation of HLA-matched and HLA-mismatched umbilical cord blood from unrelated donors: analysis of engraftment and acute graft-versus-host disease. Blood88(3), 795–802 (1996).
  • Jaroscak J, Goltry K, Smith A et al. Augmentation of umbilical cord blood (UCB) transplantation with ex vivo-expanded UCB cells: results of a Phase I trial using the Aastrom Replicell System. Blood101(12), 5061–5067 (2003).
  • Peled T, Landau E, Prus E, Treves A, Nagler A, Fibach E. Cellular copper content modulates differentiation and self-renewal in cultures of cord blood-derived CD34+ cells. Br. J. Haematol.116(3), 655–661(2002).
  • Peled T, Gluckman E, Hasson N et al. Chelatable cellular copper modulates differentiation and self-renewal of cord-blood derived hematopoietic progenitor cells. Exp. Hematol.33(10), 1092–1100 (2005).
  • De Lima M, McMannis J, Gee A et al. Transplantation of ex vivo expanded cord blood cells using the copper chelator tetraethylenepentamine: a Phase I/II clinical trial. Bone Marrow Transplant.41(9), 771–778 (2008).
  • Glimm H, Schmidt M, Fischer M et al. Efficient marking of human cells with rapid but transient repopulating activity in autografted recipients. Blood106(3), 893–898 (2005).
  • Chute JP, Muramoto GG, Salter AB et al. Transplantation of vascular endothelial cells mediates the hematopoietic recovery of lethally irradiated mice. Blood109(6), 2365–2372 (2007).
  • Salter AB, Meadows SK, Muramoto GG et al. Endothelial progenitor cell infusion induces hematopoietic stem cell reconstitution in vivo. Blood113(9), 2104–2107 (2009).
  • MacMillian ML, Blazer BR, Defor TE, Wagner JE. Transplantation of ex vivo culture-expanded parental haploidentical mesenchymal stem cells to promote engraftment in pediatric recipients of unrelated donor umbilical cord blood: results of a Phase I–II clinical trial. Bone Marrow Transplant. (2008) (Epub ahead of print).
  • Ende M, Ende N. Hematopoietic transplantation by means of fetal (cord) blood. Va Med. Mon.99(3), 276–280 (1972).
  • Margo E, Regidor C, Cabera R et al. Early hematopoietic recovery after single unit unrelated cord blood transplantation in adults supported by co-infusion of mobilized stem cells from a third party donor. Haematologica91(5), 640–648 (2006).
  • Dainiak N, Ricks RC. The evolving role of haematopoietic cell transplantation in radiation injury: potentials and limitations. BJR Suppl.27, 169–174 (2005).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.